Edinburgh: November 2019

NuCana Participated in the Piper Jaffray 31^st Annual Healthcare Conference

Edinburgh: November 2019

NuCana Presented at the Jefferies 2019 London Healthcare Conference

Edinburgh: November 2019

NuCana Reported Third Quarter 2019 Financial Results and Provided Business Update

Boston: October 2019

NuCana Presented Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Edinburgh: October 2019

NuCana Announced FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

Edinburgh: August 2019

NuCana Presented at the Morgan Stanley 17th Annual Global Healthcare Conference

Edinburgh: August 2019

NuCana Participated in Citi’s 14th Annual Biotech Conference

Edinburgh: August 2019

NuCana Reported Second Quarter 2019 Financial Results and Provided Business Update

Liverpool: August 2019

Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study Acelarate Has Been Suspended Following a Prespecified Futility Analysis

Edinburgh: July 2019

NuCana Announced First Patients Dosed in Phase I Study of NUC-7738

Edinburgh: June 2019

NuCana Received Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin^® for the Treatment of Biliary Tract Cancer

Edinburgh: May 2019

NuCana Reported First Quarter 2019 Financial Results and Provided Business Update

Edinburgh: May 2019

NuCana Presented at the Jefferies 2019 Healthcare Conference

Edinburgh: April 2019

NuCana Participated in the William Blair 3rd Late-Stage Therapeutics Conference

Edinburgh: March 2019

NuCana Reported Fourth Quarter and Year-End 2018 Financial Results and Provided Business Update

Edinburgh: March 2019

NuCana Presented at the Cowen and Company 39th Annual Health Care Conference

Edinburgh: February 2019

NuCana Presented at the American Association for Cancer Research (AACR) Annual Meeting 2019

Edinburgh: January 2019

NuCana Announced Withdrawal of Public Offering of ADSs

Edinburgh: January 2019

NuCana Announced Proposed Public Offering of ADSs

Edinburgh: November 2018

NuCana Announced First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer

Edinburgh: November 2018

NuCana Reported Third Quarter 2018 Financial Results and Provided Business Update

Edinburgh: November 2018

NuCana Participated in Citi's 2018 Global Healthcare Conference

Edinburgh: November 2018

NuCana Participated in the 2018 Evercore ISI HealthCONx Conference

Edinburgh: November 2018

NuCana Participated in the Jefferies 2018 London Healthcare Conference

Edinburgh October 2018

NuCana Presented Data from Phase I Study of NUC-3373 at ESMO 2018

Edinburgh: October 2018

NuCana Reported Additional Promising Clinical Data on NUC-1031 (Acelarin^®) as Front-Line Treatment of Advanced Biliary Tract Cancer at ESMO 2018

Edinburgh: October 2018

NuCana Presented New Data from its ProTide Portfolio at the European Society for Medical Oncology (ESMO) 2018 Congress

Edinburgh: August 2018

NuCana Participated in Citi's 13th Annual Biotech Conference.

Edinburgh: August 2018

NuCana Reported Second Quarter 2018 Financial Results and Provided Business Update
Additional Acelarin and NUC-3373 Data to be Presented at ESMO in October

Edinburgh: May 2018

NuCana CEO Hugh Griffith Honoured with the Outstanding Achievement Award From Life Sciences Scotland, NuCana also awarded Investment of the Year at awards gala in Glasgow.

Edinburgh: May 2018

NuCana Announced Appointment of Cyrille Leperlier to its Board of Directors

Edinburgh: May 2018

NuCana Reported First Quarter 2018 Financial Results

New York: May 2018

NuCana Participated in the Jefferies 2018 Global Healthcare Conference

Edinburgh: April 2018

NuCana Announced Appointment of Adam George to its Board of Directors

Edinburgh: March 2018

NuCana Reported Financial Results for the Year Ended December 31, 2017

Edinburgh: March 2018

NuCana Participated in the Cowen and Company 38th Annual Health Care Conference

Edinburgh: January 2018

NuCana Announced Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin^®) as Front-line Treatment of Advanced Biliary Tract Cancer

Edinburgh: November 2017

NuCana Participated in the Evercore ISI Biopharma Catalyst / Deep Dive Conference

Edinburgh: November 2017

NuCana Announced First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer

Edinburgh: November 2017

NuCana Presented at the Jefferies 2017 London Healthcare Conference

Edinburgh: October 2017

NuCana Announced Closing of Initial Public Offering of ADSs and Exercise of Underwriters’ Option to Purchase Additional ADSs

Edinburgh: September 2017

NuCana Announced Pricing of Initial Public Offering

Edinburgh: September 2017

NuCana Announced Interim Data from First-In-Human Study of Transformative Anti-Cancer Agent, NUC-3373 and Received Best Poster Presentation Award at ESMO 2017

Edinburgh: September 2017

NuCana Announced Positive Results of NUC-1031 (Acelarin^®) in Advanced Ovarian Cancer at ESMO 2017

Boston: March 2017

NuCana Presented at the Cowen & Company 37th Annual Healthcare Conference

New York: February 2017

NuCana Participated in the LEERINK Partners 6th Global Healthcare Conference

San Francisco: January 2017

Chicago: June 2016

NuCana’s Acelarin Achieved High Clinical Activity and Durable Disease Control in Patients with Recurrent Ovarian Cancer

Edinburgh: March 2016

NuCana’s Chief Scientific Officer, Professor Chris McGuigan

Boston: November 2015

NuCana Presented Exciting Data on Novel Anti-Cancer Agent, NUC-3373, at the AACR-NCI-EORTC Conference

Edinburgh: July 2015

NuCana Appointed Professor Chris McGuigan as Chief Scientific Officer

Chicago: May 2015

NuCana Presented Ground-Breaking Final Results of the First in Human Phase I/II Study with Acelarin in Advanced Solid Tumours at the ASCO 51st Annual Meeting

Chicago: May 2015

Acelarin achieved Very High Disease Control Rates in Patients with Advanced Gynaecological Cancers in a Phase I/II Setting. Study Results Presented at the ASCO 51st Annual Meeting

Philadelphia: April 2015

NuCana Presented Data on the Molecular Diagnostics Programme for Acelarin at the AACR Annual Meeting

Edinburgh: December 2014

NuCana Appointed Dr. Paolo Paoletti to its Board of Directors

Chicago: May 2014

Acelarin Achieved High Disease Control Rate in Patients with Advanced Cancer.ProGem1 Study Results Presented at the ASCO 50th Annual Meeting

Edinburgh: April 2014

NuCana Announced a Series B Financing of $57 Million to Fund Expansion of Clinical Studies with its Anti-Cancer ProTides

San Diego: April 2014

NuCana Presented Exceptional Data for Anti-Cancer Agent, Acelarin, at the AACR Annual Meeting

San Diego: March 2014

NuCana Presented at AACR

Edinburgh: February 2014

Important Results of NuCana’s lead ProTide published in prominent scientific journal

Edinburgh: September 2013

NuCana Attended ESMO 2013 in Amsterdam

Edinburgh: July 2013

NuCana Highlighted EvaluatePharma Report Valuing the Industries Pipeline Products. ProTide Technology Takes Number One Position

Cardiff: June 2013

'Drug hunter' Chris McGuigan on NuCana and Medical Research Excitement

Chicago: June 2013

Encouraging Results from the ProGem1 Study of Acelarin (NUC-1031) in Patients with Advanced Cancer Presented at ASCO 2013

Edinburgh: May 2013

NuCana Presented Phase I Clinical Data at ASCO 2013

Edinburgh: April 2013

NuCana Presented at BioEquity Europe

Edinburgh: April 2013

NuCana Appointed Erwan Lejeune as Scientific Affairs Manager.

Edinburgh: March 2013

NuCana Presented at BioTrinity

Edinburgh: February 2013

NuCana Ups and Downs of a Drug Hunter - from the Lab to Patients

A lecture by Prof. Chris McGuigan as Part of the 'Science in Health' Public Lecture Series at Cardiff University

Edinburgh: February 2013

NuCana - Pioneering Pair Invest in a Healthy Future.

Edinburgh: February 2013

NuCana Biomed Announced as Joint Winners of the Investment of the Year (2012) Award.

Edinburgh: February 2013

NuCana Joint Winners of the Investment of the Year (2012) Award

Edinburgh: May 2012

NuCana Announced the Appointment of Ian Abercrombie as Chief Operating Officer

Edinburgh: November 2011

NuCana Secured $10.4 million Series A Financing to Accelerate it's ProTide Anti-Cancer Drugs into Clinical Development

International: November 2011

NuCana Gets $10.5M for ProTide Cancer Drugs

Scotland: November 2011

Life Science Specialists £6.7m for New Venture

Wales: November 2011

Welsh Scientists Could Prevent Cancer Cells Becoming Resistant to Drugs

Edinburgh: February 2011

NuCana Announced it had Completed a Further Equity Financing that will Enable NuCana's First Product to Enter Clinical Development

Edinburgh: February 2011

Hugh Griffth was a Keynote Speaker at the Prestigious Scottish Enterprise Life Sciences Annual Dinner

Cardiff: January 2011

Chris Wood Presented at Cardiff University EPSRC/PRESIDENTS ENTREPRENEURSHIP DAY on Discovering New Medicines & Making Money

Edinburgh: December 2010

NuCana Announced the Appointment of Martin Mellish as Non Executive Director to the Board of Directors

Edinburgh: June 2010

Hugh Griffith was Guest Speaker at BIA and Ernst & Young Beyond Borders Seminar

Edinburgh: May 2010

Hugh Griffith Provided a Vision for Challenges Facing Biotechnology in the Foreword to Marks & Clerk Life Sciences Report 2010

Cardiff: April 2010

Christopher Wood Presented at Wales Cancer Conference

Edinburgh: February 2010

Hugh Griffith Presented at BIA Scotland BioLeadership Forum and Dinner

Edinburgh: December 2009

NuCana Completed Financing to Expand Anti-Cancer Drug Development Programme.

Edinburgh: December 2009

Alida Capital International Completed Financing into NuCana BioMed.

Cardiff: November 2009

Morvus Technology and NuCana Signed Exclusive World-wide Licence to Develop ProTide Technology in Cancer.